Published in Cancer Metastasis Rev on March 01, 2014
The changing landscape of phase I trials in oncology. Nat Rev Clin Oncol (2015) 0.79
Phospho-kinase profile of colorectal tumors guides in the selection of multi-kinase inhibitors. Oncotarget (2015) 0.77
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst (2010) 3.94
Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol (2012) 3.56
Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol (2011) 3.46
Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst (2011) 2.66
Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated shedding. Mol Biol Cell (2002) 2.54
Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst (2013) 2.54
The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol (2012) 1.98
Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol Cell Biol (2008) 1.95
Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol (2009) 1.95
Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer (2014) 1.93
Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res (2011) 1.79
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res (2006) 1.67
Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood (2005) 1.66
Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2. Mol Cell Biol (2002) 1.64
Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. J Clin Oncol (2011) 1.43
Mathematics in the realm of lapatinib: 500 + 500 = 1,500? J Clin Oncol (2008) 1.42
New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol (2008) 1.41
In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica (2009) 1.38
HER3 overexpression and survival in solid tumors: a meta-analysis. J Natl Cancer Inst (2012) 1.37
Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations. Drugs (2011) 1.36
Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target. PLoS One (2009) 1.35
Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials. J Clin Oncol (2013) 1.28
Preclinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol (2010) 1.27
Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. J Clin Oncol (2010) 1.22
Multifunctional role of Erk5 in multiple myeloma. Blood (2005) 1.22
Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res (2005) 1.21
Neuregulins and cancer. Clin Cancer Res (2008) 1.21
Sunitinib in solid tumors. Expert Opin Investig Drugs (2009) 1.20
Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists. Support Care Cancer (2011) 1.17
Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. Blood (2008) 1.17
Impaired trafficking and activation of tumor necrosis factor-alpha-converting enzyme in cell mutants defective in protein ectodomain shedding. J Biol Chem (2003) 1.16
Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer. J Clin Oncol (2007) 1.16
Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer? Eur J Cancer (2011) 1.16
CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype. Haematologica (2012) 1.14
The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype. Haematologica (2008) 1.13
Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res (2008) 1.11
Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin. Cancer Res (2005) 1.09
Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells. J Natl Cancer Inst (2010) 1.07
Multidimensional challenges in clinical drug development, regulatory approval, and marketing. J Clin Oncol (2013) 1.07
ERK5 activates NF-kappaB in leukemic T cells and is essential for their growth in vivo. J Immunol (2006) 1.06
Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer. Am J Clin Oncol (2013) 1.05
Should a biopsy be recommended to confirm metastatic disease in women with breast cancer? Lancet Oncol (2009) 1.05
Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis. Breast Cancer Res Treat (2010) 1.03
Cost-effectiveness of outpatient management for febrile neutropenia in children with cancer. Pediatrics (2011) 1.03
Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation. Clin Cancer Res (2010) 1.01
Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases. Biochem J (2002) 1.01
Endoglin modulation of TGF-beta1-induced collagen synthesis is dependent on ERK1/2 MAPK activation. Cell Physiol Biochem (2006) 1.00
Genetic polymorphisms as predictive and prognostic biomarkers in gynecological cancers: a systematic review. Gynecol Oncol (2011) 1.00
CCN3 impairs osteoblast and stimulates osteoclast differentiation to favor breast cancer metastasis to bone. Am J Pathol (2011) 0.99
Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions. Cancer Treat Rev (2009) 0.98
Multisite phosphorylation of Erk5 in mitosis. J Cell Sci (2010) 0.95
Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity. Haematologica (2008) 0.95
Cellular plasticity confers migratory and invasive advantages to a population of glioblastoma-initiating cells that infiltrate peritumoral tissue. Stem Cells (2013) 0.95
Identifying breast cancer druggable oncogenic alterations: lessons learned and future targeted options. Clin Cancer Res (2008) 0.95
Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes. Mol Cell Biol (2012) 0.95
p53 Arg72Pro polymorphism, HPV status and initiation, progression, and development of cervical cancer: a systematic review and meta-analysis. Clin Cancer Res (2012) 0.95
Approach to inflammatory breast cancer. Can Fam Physician (2009) 0.95
Deficient spindle assembly checkpoint in multiple myeloma. PLoS One (2011) 0.94
Mismatch repair status and clinical outcome in endometrial cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol (2013) 0.94
Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer (2005) 0.93
Targeting DNA repair in breast cancer: a clinical and translational update. Cancer Treat Rev (2010) 0.93
Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands. Int J Oncol (2012) 0.93
A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events. Breast Cancer Res Treat (2014) 0.93
A new method for detecting TNF-alpha-secreting cells using direct-immunofluorescence surface membrane stainings. J Immunol Methods (2002) 0.92
Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications. Mol Cancer Ther (2012) 0.92
Role of metalloproteinases MMP-9 and MT1-MMP in CXCL12-promoted myeloma cell invasion across basement membranes. J Pathol (2006) 0.91
Endoglin expression regulates basal and TGF-beta1-induced extracellular matrix synthesis in cultured L6E9 myoblasts. Cell Physiol Biochem (2004) 0.91
Mechanism of apoptosis induced by IFN-alpha in human myeloma cells: role of Jak1 and Bim and potentiation by rapamycin. Cell Signal (2006) 0.90
Vascular endothelial growth factor pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a systematic review and meta-analysis. Clin Cancer Res (2012) 0.90
Overexpression of HER2 signaling to WAVE2-Arp2/3 complex activates MMP-independent migration in breast cancer. Breast Cancer Res Treat (2010) 0.90
ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy. PLoS One (2009) 0.89
Pharmacogenetic and germline prognostic markers of lung cancer. J Thorac Oncol (2011) 0.89
Erk5 is activated and acts as a survival factor in mitosis. Cell Signal (2007) 0.89
Do we have to change the way targeted drugs are developed? J Clin Oncol (2010) 0.88
The evolving landscape of protein kinases in breast cancer: clinical implications. Cancer Treat Rev (2012) 0.88
Erk5 nuclear location is independent on dual phosphorylation, and favours resistance to TRAIL-induced apoptosis. Cell Signal (2007) 0.88
Personalized therapies in the cancer "omics" era. Mol Cancer (2010) 0.88
Defining ovarian failure in amenorrheic young breast cancer patients. Breast (2010) 0.88
Phosphorylation of P-Rex1 at serine 1169 participates in IGF-1R signaling in breast cancer cells. Cell Signal (2013) 0.87
ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone. Breast Cancer Res (2012) 0.86
Autophagy inhibition sensitizes multiple myeloma cells to 17-dimethylaminoethylamino-17-demethoxygeldanamycin-induced apoptosis. Leuk Res (2010) 0.86
Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects. PLoS One (2012) 0.85
Targeting HER receptors in cancer. Curr Pharm Des (2013) 0.85
The mitogen-activated protein kinase Erk5 mediates human mesangial cell activation. Nephrol Dial Transplant (2008) 0.85
Potent antimyeloma activity of a novel ERK5/CDK inhibitor. Clin Cancer Res (2013) 0.85
The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells. Br J Haematol (2008) 0.85
A new simple whole blood flow cytometry-based method for simultaneous identification of activated cells and quantitative evaluation of cytokines released during activation. Lab Invest (2004) 0.85
Medical oncology: Zoledronic acid for breast cancer therapy-induced bone loss. Nat Rev Clin Oncol (2010) 0.83
Benefits and harms of detecting clinically occult breast cancer. J Natl Cancer Inst (2012) 0.83